Clinical Trial

A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous Non-small Cell Lung Cancer

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
To evaluate the safety and efficacy of SYS6010 combined with osimertinib as neoadjuvant therapy for patients with resectable EGFR mutation non-squamous non-small cell lung cancer.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-11-20.
Trial Details
NCT Number NCT07256509
Lead Sponsor CSPC Megalith Biopharmaceutical Co.,Ltd.
Conditions Non-Small Cell Lung Cancer
Enrollment 120 participants
Start Date 2025-11-30
Primary Completion 2026-11-30 (estimated)
Study Completion 2032-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-12-05